Jade Biosciences, Inc. (NASDAQ: JBIO) is a Healthcare company (Biotechnology) with a market capitalization of $979M. The Maz Rating grades it against the other companies in its sector.
Jade Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $15.40, Jade Biosciences, Inc. trades at 2.4x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -42.8%, return on invested capital of -38.8% and a free cash flow yield of -13.3%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 16.03. Over the past 52 weeks the share price ranged from $11.02 to $28.00, with a beta of 1.45.
Jade Biosciences, Inc. does not currently pay a dividend.
4 Wall Street analyst ratings cover the stock: 4 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.